HC Wainwright Has Optimistic Outlook of RLAY Q1 Earnings

Relay Therapeutics, Inc. (NASDAQ:RLAY) – Investment analysts at HC Wainwright lifted their Q1 2026 earnings estimates for shares of Relay Therapeutics in a note issued to investors on Monday, March 23rd. HC Wainwright analyst R. Burns now forecasts that the company will earn ($0.36) per share for the quarter, up from their prior forecast of ($0.43). HC Wainwright currently has a “Buy” rating and a $19.00 price target on the stock. The consensus estimate for Relay Therapeutics’ current full-year earnings is ($2.55) per share. HC Wainwright also issued estimates for Relay Therapeutics’ Q2 2026 earnings at ($0.37) EPS, Q3 2026 earnings at ($0.38) EPS, Q4 2026 earnings at ($0.38) EPS and FY2026 earnings at ($1.49) EPS.

Other research analysts have also recently issued research reports about the company. Guggenheim lifted their target price on Relay Therapeutics from $15.00 to $22.00 and gave the company a “buy” rating in a research report on Friday, March 13th. Wells Fargo & Company increased their price target on Relay Therapeutics from $15.00 to $17.00 and gave the company an “overweight” rating in a research report on Tuesday, March 17th. Oppenheimer restated an “outperform” rating on shares of Relay Therapeutics in a research note on Monday, March 16th. Citizens Jmp lifted their price objective on shares of Relay Therapeutics from $15.00 to $17.00 and gave the stock a “market outperform” rating in a report on Tuesday, March 17th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Relay Therapeutics in a research note on Friday, January 9th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Relay Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $18.00.

Relay Therapeutics Stock Down 3.9%

Shares of Relay Therapeutics stock opened at $9.44 on Wednesday. Relay Therapeutics has a 52 week low of $1.77 and a 52 week high of $11.49. The business has a 50 day moving average price of $8.98 and a 200-day moving average price of $7.54. The company has a market cap of $1.69 billion, a PE ratio of -5.83 and a beta of 1.55.

Relay Therapeutics (NASDAQ:RLAY) last released its quarterly earnings results on Thursday, February 26th. The company reported ($0.32) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.38) by $0.06. The company had revenue of $7.00 million for the quarter, compared to analyst estimates of $4.34 million.

Hedge Funds Weigh In On Relay Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Torren Management LLC purchased a new position in shares of Relay Therapeutics in the 4th quarter worth about $30,000. Smartleaf Asset Management LLC increased its holdings in Relay Therapeutics by 288.6% during the fourth quarter. Smartleaf Asset Management LLC now owns 4,426 shares of the company’s stock worth $37,000 after buying an additional 3,287 shares during the last quarter. Caitong International Asset Management Co. Ltd bought a new stake in Relay Therapeutics in the fourth quarter worth about $46,000. Mirae Asset Global Investments Co. Ltd. raised its position in Relay Therapeutics by 26.4% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 8,422 shares of the company’s stock worth $71,000 after acquiring an additional 1,757 shares during the period. Finally, Abel Hall LLC purchased a new position in Relay Therapeutics in the third quarter valued at about $58,000. 96.98% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Relay Therapeutics news, CEO Sanjiv Patel sold 43,168 shares of the business’s stock in a transaction on Tuesday, January 6th. The stock was sold at an average price of $7.82, for a total value of $337,573.76. Following the transaction, the chief executive officer owned 661,041 shares of the company’s stock, valued at approximately $5,169,340.62. The trade was a 6.13% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Peter Rahmer sold 11,684 shares of the company’s stock in a transaction on Tuesday, January 27th. The shares were sold at an average price of $7.62, for a total value of $89,032.08. Following the completion of the transaction, the insider owned 277,964 shares of the company’s stock, valued at $2,118,085.68. This trade represents a 4.03% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 93,302 shares of company stock valued at $724,355. Insiders own 4.32% of the company’s stock.

Relay Therapeutics Company Profile

Relay Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of precision therapies for oncology. Headquartered in Cambridge, Massachusetts, the company was founded in 2016 with the goal of targeting dynamic protein motion using an integrated scientific platform. Relay Therapeutics leverages computational modeling, structural biology, and experimental validation to identify small-molecule drug candidates that modulate the behavior of disease-associated proteins.

The company’s core business activity centers on its proprietary drug-discovery engine, which combines high-performance computing—including molecular dynamics simulations—with advanced experimental techniques such as cryo-electron microscopy and biophysical screening.